Israeli biopharma firm BiomX raised $32 million in a private funding round that will primarily be used to advance the company’s drug candidates for the treatment of acne and inflammatory bowel disease (IBD).
Activist hedge fund Starboard Value LP asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co. shareholders for the U.S. drug maker’s $74 billion deal to buy Celgene Corp., people familiar with the matter said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The tools of artificial intelligence continue to be essential elements for the biopharma industry. Companies across the sphere have invested heavily into the technology and this week, several more announced deals that bank on the use of artificial intelligence.
Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.
While some manufacturing industries have long utilized automation throughout their processes and product production, the biopharma industry is comparatively behind the times.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.
The FDA issued draft guidance for biopharma companies on developing therapies for NASH with liver fibrosis.
Biopharma executives were asked to predict what the next year might reveal.
Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.